The Thalamus and Multiple Sclerosis
Neurol 80:210-219, Minagar, A.,et al, 2013
JC Virus Infection of the Brain
AJNR 31:1564-1576, Bag,A.K.,et al, 2010
Tumefactive Multiple Sclerosis
www.medlink.com, JUne, Bunyan, R.F. and Lucchinetti, C.F., 2010
Sexual Function in Men and Women With Neurological Disorders
Lancet 369:512-525, Rees,P.M.,et al, 2007
Guidelines For Using Proton MR Spectroscopy in Multicenter Clinical MS Studies
Neurol 69:1942-1952, De Stefano,N.,et al, 2007
Balos Concentric Sclerosis Presenting as a Stroke-Like Syndrome
Nat Clin Pract Neurol 3:349-354, Mowry,E.M.,et al, 2007
Multiple Sclerosis: The Role of MR Imaging
AJNR 27:1165-1176, Ge,Y., 2006
Evidence for Widespread Axonal Damage at the Earliest Clinical Stage of Multiple Sclerosis
Brain 126:433-437, Filippi,M.,et al, 2003
Proton MR Spectroscopy of Tumefactive Demyelinating Lesions
AJNR 23:1378-1386, Saindane,A.M.,et al, 2002
Multiple Sclerosis and Magnetic Resonance Imaging
Arch Neurol 58:35-36, Racke,M.K.,et al, 2001
Total Brain N-Acetylaspartate, A New Measure of Disease Load in MS
Neurol 54:15-19, Gonen,O.,et al, 2000
Axonal Transection in the Lesions of Multiple Sclerosis
NEJM 338:278-285, 3231998., Trapp,B.D.,et al, 1998
Imaging the Brain, Part 1 & 2
NEJM 338:812-820, 889-8961998., Gilman,S., 1998
Physiologic MRI of a Tumefactive Multiple Sclerosis Lesion
Neurol 51:1487-1488, Ernst,T.,et al, 1998
Proton MR Spectroscopy in Multiple Sclerosis:Value in Establishing Diagnosis, Monitoring Progression, and Evaluating Therapy
AJR 157:1073-1078, Richards,T.L., 1991
The Optic Nerve Should Graduate to Be the Fifth Lesion Site for the Diagnosis of Multiple Sclerosis
Neurol 102:e207919, Galetta,S. & Brownlee, W., 2024
Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024
Diagnostic MRI Score to Differentiate Susac Syndrome from Primary Angiitis of the Central Nervous System and Multiple Sclerosis
Ann Neurol 96:846-854, Marrodan,M.,et al, 2024
Slowly Expanding Lesions Differentiate Pediatric Multiple Sclerosis from Myelin Oligodendrocyte Glycoprotein Antibody Disease
Ann Neurol 96:1086-1091, Fadda,G.,et al, 2024
Management of Possible Multiple Sclerosis
NEJM 388:2195-2190, , 2023
Drug-Related Demyelinating Syndromes: Understanding Risk Factors, Pathophysiological Mechanisms and Magnetic Resonance Imaging Findings
Mult Scler Rel Dis 55:103146, Rimkus, C.M.,et al, 2021
Telemedicine in Neurology
Neurol 94:30-38,16, Hatcher-Martin, J.M.,et al, 2020
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Comorbidity is Associated with Disease Activity in MS
Neurol 95:e446-e456, Salter, A.,et al, 2020
Radiologically Isolated Syndrome: A Review for Neuroradiologists
AJNR 41:1542-1549, Hosseiny, M.,et al, 2020
Paramagnetic Rim Lesions are Specific to Multiple Sclerosis:An International Multicenter 3T MRI Study
Ann Neurol 88:1034-1042, Maggi,P.,et al, 2020
Evaluation of the Central Vein Sign as a Diagnostic Imaging Biomarker in Multiple Sclerosis
JAMA Neurol 76:1446-1456, Sinnecker, T.,et al, 2019
Evaluation of Idiopathic Transverse Myelitis Revealing Specific Myelopathy Diagnoses
Neurol 90:e96-102, Zalewski, N.L.,et al, 2018
Multiple Sclerosis
NEJM 378:169-180, Reich, D.S.,et al, 2018
Value of the Central Vein Sign at 3T to Differentiate MS from Seropositive NMOSD
Neurol 90:e1183-e1190, Cortese, R.,et al, 2018
Progressive multifocal leukoencephalpathy after fingolimod treatment
Neurol 90:1815-e1821, Berger, J.R.,et al, 2018
Prodromal Symptoms of Multiple Sclerosis in Primary Care
Ann Neurol 83:1162-1173, Disanto,G.,et al, 2018
Application of the 2017 Revised McDonald Criteria for Multiple Sclerosis to Patients with a Typical Clinically Isolated Syndrome
JAMA Neurol 75:1392-1398, Van Der Vuurst De Vries, R.M.,et al, 2018
Natalizumab-Associated PML
Neurol 88:1197-1205, Schwab, N.,et al, 2017
Diagnosis of Multiple Sclerosis: Progress and Challenges
Lancet 389:1336-1346, Brownlee, W.J.,et al, 2017
Dentate Update: Imaging Features of Entities that Affect the Dentate Nucleus
AJNR 38:1467-1474, Bond, K.M.,et al, 2017
Acute Disseminated Encephalomyelitis in 228 Patients
Neurol 86:2085-2096, Koelman, D.L.H.,et al, 2016
The Contemporary Spectrum of Multiple Sclerosis Misdiagnosis
Neurol 87:1393-1399, Solomon, A.J.,et al, 2016
Varicella-Zoster Virus Infections in Patients Treated with Fingolimod
JAMA Neurol 72:31-39,10, Arvin, A.M.,et al, 2015
Cardiovascular Dysfunction in Multiple Sclerosis
Neurologist 20:108-114, Kaplan, T.B.,et al, 2015
Effect of high-dose Simvastatin on Brain Atrophy and Disability in Secondary Progressive Multiple Sclerosis (MS-STAT): A Randomised, Placebo-Controlled, Phase 2 Trial
Lancet 383:2213-2221, Chataway, J.,et al, 2014
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
Intensive Care Unit Admission in Multiple Sclerosis
Neurol 82:2112-2119, Marrie, R.A.,et al, 2014
The Etiology of Ring Lesions on Diffusion-Weighted Imaging
NeuroRadiol J 27:280-287, Finelli, P. & Foxman, E.B., 2014
Palliative Care and Neurology
Neurol 83:561-567, Boersma, I.,et al, 2014
The Management of Spasticity in Adults
BMJ 349:g4737, Nair, K.P.S. & Marsden, J., 2014
Spinal Cord Lesions in Patients with Clinically Isolated Syndrome
Neurol 80:69-75, Sombekke, M.,et al, 2013
Location of Brain Lesions Predicts Conversion of Clinically Isolated Syndromes to Multiple Sclerosis
Neurol 80:234-241, Giorgio, A.,et al, 2013
Tumor Necrosis Factor-Alpha Inhibitors: An Overview of Adverse Effects
UpToDate January, Stone, J.H., 2013